Abstract
Recalcitrant wounds pose a challenge to the dermatologist. In recent years, many skin substitutes have been developed and are broadly classified as either acellular or cellular. These skin substitutes are to be used in concert with standard of care to provide the stalled wound with a scaffold and key elements such as cytokines, growth factors, and extracellular matrix substances. Skin substitutes help initiate and accelerate wound healing through granulation, cell migration, re-vascularization, and re-epithelialization. Wounds of varying etiologies have been shown to benefit from the multitude of acellular and cellular skin substitutes that are available. This chapter provides clinically relevant background and practical guidance about skin substitutes to allow dermatologists to effectively incorporate these powerful tools into their wound healing armamentarium.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- BLCCs:
-
Bilayered living cellular constructs
- CA:
-
Cadaveric allograft
- CDM:
-
Collagen dermal matrix
- CEAs:
-
Cultured epidermal autografts
- CPM:
-
Cryopreserved placental membrane
- DFU:
-
Diabetic foot ulcer
- DHACM:
-
Dehydrated human amnion/chorion membrane
- DRT:
-
Dermal regeneration template
- ECM:
-
Extracellular matrix
- PU:
-
Pressure ulcer
- VLU:
-
Venous leg ulcer
References
Ramanujam CL, Zgonis T. An overview of autologous skin grafts and advanced biologics for the diabetic foot. Clin Podiatr Med Surg. 2012;29(3):435–41.
Mazzola IC, Mazzola RF. History of reconstructive rhinoplasty. Facial Plast Surg. 2014;30(3):227–36.
Halim AS, Khoo TL, Mohd Yussof SJ. Biologic and synthetic skin substitutes: an overview. Indian J Plast Surg. 2010;43(Suppl):S23–8.
Rheinwald JG, Green H. Serial cultivation of strains of human epidermal keratinocytes: the formation of keratinizing colonies from single cells. Cell. 1975;6(3):331–43.
Burke JF, Yannas IV, Quinby WC Jr, Bondoc CC, Jung WK. Successful use of a physiologically acceptable artificial skin in the treatment of extensive burn injury. Ann Surg. 1981;194(4):413–28.
Yannas IV, Burke JF, Orgill DP, Skrabut EM. Wound tissue can utilize a polymeric template to synthesize a functional extension of skin. Science. 1982;215(4529):174–6.
Woo K, Ayello EA, Sibbald RG. The edge effect: current therapeutic options to advance the wound edge. Adv Skin Wound Care. 2007;20(2):99–117; quiz 8–9.
Stone RC, Stojadinovic O, Rosa AM, Ramirez HA, Badiavas E, Blumenberg M, et al. A bioengineered living cell construct activates an acute wound healing response in venous leg ulcers. Sci Transl Med. 2017;9(371).
Kallis PJ, Friedman AJ, Lev-Tov H. A guide to tissue-engineered skin substitutes. J Drugs Dermatol. 2018;17(1):57–64.
Sinha S, Schreiner AJ, Biernaskie J, Nickerson D, Gabriel VA. Treating pain on skin graft donor sites: review and clinical recommendations. J Trauma Acute Care Surg. 2017;83(5):954–64.
Nicholas MN, Jeschke MG, Amini-Nik S. Methodologies in creating skin substitutes. Cell Mol Life Sci. 2016;73(18):3453–72.
Clark RA, Ghosh K, Tonnesen MG. Tissue engineering for cutaneous wounds. J Invest Dermatol. 2007;127(5):1018–29.
Nathoo R, Howe N, Cohen G. Skin substitutes: an overview of the key players in wound management. J Clin Aesthet Dermatol. 2014;7(10):44–8.
Shores JT, Gabriel A, Gupta S. Skin substitutes and alternatives: a review. Adv Skin Wound Care. 2007;20(9 Pt 1):493–508; quiz 9–10.
Lazarus GS, Cooper DM, Knighton DR, Margolis DJ, Pecoraro RE, Rodeheaver G, et al. Definitions and guidelines for assessment of wounds and evaluation of healing. Arch Dermatol. 1994;130(4):489–93.
Broussard KC, Powers JG. Wound dressings: selecting the most appropriate type. Am J Clin Dermatol. 2013;14(6):449–59.
Morton LM, Phillips TJ. Wound healing and treating wounds: Differential diagnosis and evaluation of chronic wounds. J Am Acad Dermatol. 2016;74(4):589–605; quiz −6.
Childs DR, Murthy AS. Overview of wound healing and management. Surg Clin North Am. 2017;97(1):189–207.
Daugherty S, Spear M. Skin and skin substitutes–an overview. Plast Surg Nurs. 2015;35(2):92–7.
Apligraf Label. Available from: http://www.apligraf.com/professional/pdf/prescribing_information.pdf.
Dermagraft label. Available from: http://www.dermagraft.com/home/wp-content/uploads/sites/1/Dermagraft_Directions_for_Use.pdf.
Integra Flowable Matrix Label. Available from: http://occ.integralife.com/products%2Fpdfs%2Fflowable_wound_matrix_ifu.pdf.
Gardien KL, Marck RE, Bloemen MC, Waaijman T, Gibbs S, Ulrich MM, et al. Outcome of burns treated with autologous cultured proliferating epidermal cells: a prospective randomized multicenter Intrapatient comparative trial. Cell Transplant. 2016;25(3):437–48.
Hickerson WL, Remmers AE, Recker D. Twenty-five years’ experience and beyond with Cultured Epidermal Autografts (CEA) for coverage of large burn wounds in adult and pediatric patients, 1989–2015. J Burn Care Res. 2019;40(2):157–65.
Sood R, Roggy D, Zieger M, Balledux J, Chaudhari S, Koumanis DJ, et al. Cultured epithelial autografts for coverage of large burn wounds in eighty-eight patients: the Indiana University experience. J Burn Care Res. 2010;31(4):559–68.
Falanga V, Sabolinski M. A bilayered living skin construct (APLIGRAF) accelerates complete closure of hard-to-heal venous ulcers. Wound Repair Regen. 1999;7(4):201–7.
Edmonds M. Apligraf in the treatment of neuropathic diabetic foot ulcers. Int J Low Extrem Wounds. 2009;8(1):11–8.
Zelen CM, Serena TE, Gould L, Le L, Carter MJ, Keller J, et al. Treatment of chronic diabetic lower extremity ulcers with advanced therapies: a prospective, randomised, controlled, multi-centre comparative study examining clinical efficacy and cost. Int Wound J. 2016;13(2):272–82.
Marston WA, Hanft J, Norwood P, Pollak R. The efficacy and safety of Dermagraft in improving the healing of chronic diabetic foot ulcers: results of a prospective randomized trial. Diabetes Care. 2003;26(6):1701–5.
Gentzkow GD, Iwasaki SD, Hershon KS, Mengel M, Prendergast JJ, Ricotta JJ, et al. Use of dermagraft, a cultured human dermis, to treat diabetic foot ulcers. Diabetes Care. 1996;19(4):350–4.
Noordenbos J, Dore C, Hansbrough JF. Safety and efficacy of TransCyte for the treatment of partial-thickness burns. J Burn Care Rehabil. 1999;20(4):275–81.
Kumar RJ, Kimble RM, Boots R, Pegg SP. Treatment of partial-thickness burns: a prospective, randomized trial using Transcyte. ANZ J Surg. 2004;74(8):622–6.
Zelen CM, Gould L, Serena TE, Carter MJ, Keller J, Li WW. A prospective, randomised, controlled, multi-centre comparative effectiveness study of healing using dehydrated human amnion/chorion membrane allograft, bioengineered skin substitute or standard of care for treatment of chronic lower extremity diabetic ulcers. Int Wound J. 2015;12(6):724–32.
Zelen CM, Serena TE, Denoziere G, Fetterolf DE. A prospective randomised comparative parallel study of amniotic membrane wound graft in the management of diabetic foot ulcers. Int Wound J. 2013;10(5):502–7.
Serena TE, Carter MJ, Le LT, Sabo MJ, DiMarco DT. A multicenter, randomized, controlled clinical trial evaluating the use of dehydrated human amnion/chorion membrane allografts and multilayer compression therapy vs. multilayer compression therapy alone in the treatment of venous leg ulcers. Wound Repair Regen. 2014;22(6):688–93.
Bianchi C, Cazzell S, Vayser D, Reyzelman AM, Dosluoglu H, Tovmassian G. A multicentre randomised controlled trial evaluating the efficacy of dehydrated human amnion/chorion membrane (EpiFix((R))) allograft for the treatment of venous leg ulcers. Int Wound J. 2018;15(1):114–22.
Lavery L, Fulmer J, Shebetka KA, Regulski M, Vayser D, Fried D, et al. Open-label extension phase of a chronic diabetic foot ulcer multicenter, controlled, randomized clinical trial using cryopreserved placental membrane. Wounds. 2018;30(9):283–9.
Lavery LA, Fulmer J, Shebetka KA, Regulski M, Vayser D, Fried D, et al. The efficacy and safety of Grafix((R)) for the treatment of chronic diabetic foot ulcers: results of a multi-centre, controlled, randomised, blinded, clinical trial. Int Wound J. 2014;11(5):554–60.
The Oxford 2011 Levels of Evidence: Oxford Centre for Evidence-Based Medicine. Available from: http://www.cebm.net/index.aspx?o=5653.
Ehrenreich M, Ruszczak Z. Update on tissue-engineered biological dressings. Tissue Eng. 2006;12(9):2407–24.
Leary T, Jones PL, Appleby M, Blight A, Parkinson K, Stanley M. Epidermal keratinocyte self-renewal is dependent upon dermal integrity. J Invest Dermatol. 1992;99(4):422–30.
Epicel Guidelines. Available from: https://www.epicel.com/pdfs/Epicel%20SurgicalGuide%202018%20DIGITAL.pdf.
Ronfard V, Rives JM, Neveux Y, Carsin H, Barrandon Y. Long-term regeneration of human epidermis on third degree burns transplanted with autologous cultured epithelium grown on a fibrin matrix. Transplantation. 2000;70(11):1588–98.
Wood FM, Kolybaba ML, Allen P. The use of cultured epithelial autograft in the treatment of major burn injuries: a critical review of the literature. Burns. 2006;32(4):395–401.
Chester DL, Balderson DS, Papini RP. A review of keratinocyte delivery to the wound bed. J Burn Care Rehabil. 2004;25(3):266–75.
Williamson JS, Snelling CF, Clugston P, Macdonald IB, Germann E. Cultured epithelial autograft: five years of clinical experience with twenty-eight patients. J Trauma. 1995;39(2):309–19.
Atiyeh BS, Costagliola M. Cultured epithelial autograft (CEA) in burn treatment: three decades later. Burns. 2007;33(4):405–13.
Holmes Iv JH, Molnar JA, Carter JE, Hwang J, Cairns BA, King BT, et al. A comparative study of the ReCell(R) device and autologous spit-thickness meshed skin graft in the treatment of acute burn injuries. J Burn Care Res. 2018;39(5):694–702.
Vig K, Chaudhari A, Tripathi S, Dixit S, Sahu R, Pillai S, et al. Advances in skin regeneration using tissue engineering. Int J Mol Sci. 2017;18(4).
Duchini G, Itin P, Arnold A. A case of refractory pyoderma gangrenosum treated with a combination of Apligraf and systemic immunosuppressive agents. Adv Skin Wound Care. 2011;24(5):217–20.
Trent JT, Kirsner RS. Epidermolysis bullosa: identification and treatment. Adv Skin Wound Care. 2003;16(6):284–90.
Hayes DW Jr, Webb GE, Mandracchia VJ, John KJ. Full-thickness burn of the foot: successful treatment with Apligraf. A case report. Clin Podiatr Med Surg. 2001;18(1):179–88.
Shealy FG Jr, DeLoach ED. Experience with the use of apligraf to heal complicated surgical and nonsurgical wounds in a private practice setting. Adv Skin Wound Care. 2006;19(6):310–22.
Dinh TL, Veves A. The efficacy of Apligraf in the treatment of diabetic foot ulcers. Plast Reconstr Surg. 2006;117(7 Suppl):152S–7S; discussion 8S–9S.
Bello YM, Falabella AF, Eaglstein WH. Tissue-engineered skin. Current status in wound healing. Am J Clin Dermatol. 2001;2(5):305–13.
Zaulyanov L, Kirsner RS. A review of a bi-layered living cell treatment (Apligraf) in the treatment of venous leg ulcers and diabetic foot ulcers. Clin Interv Aging. 2007;2(1):93–8.
Schonfeld WH, Villa KF, Fastenau JM, Mazonson PD, Falanga V. An economic assessment of Apligraf (Graftskin) for the treatment of hard-to-heal venous leg ulcers. Wound Repair Regen. 2000;8(4):251–7.
Harding K, Sumner M, Cardinal M. A prospective, multicentre, randomised controlled study of human fibroblast-derived dermal substitute (Dermagraft) in patients with venous leg ulcers. Int Wound J. 2013;10(2):132–7.
Purdue GF, Hunt JL, Still JM Jr, Law EJ, Herndon DN, Goldfarb IW, et al. A multicenter clinical trial of a biosynthetic skin replacement, Dermagraft-TC, compared with cryopreserved human cadaver skin for temporary coverage of excised burn wounds. J Burn Care Rehabil. 1997;18(1 Pt 1):52–7.
Sheikh ES, Sheikh ES, Fetterolf DE. Use of dehydrated human amniotic membrane allografts to promote healing in patients with refractory non healing wounds. Int Wound J. 2014;11(6):711–7.
Miranda EP, Friedman A. Dehydrated human amnion/chorion grafts may accelerate the healing of ulcers on free flaps in patients with venous insufficiency and/or lymphedema. Eplasty. 2016;16:e26.
Hughes OB, Rakosi A, Macquhae F, Herskovitz I, Fox JD, Kirsner RS. A review of cellular and acellular matrix products: indications, techniques, and outcomes. Plast Reconstr Surg. 2016;138(3 Suppl):138s–47s.
Epifix instructions. Available from: https://www.woundsource.com/print/product/epifix-dehydrated-human-amnionchorion-membrane-allograft.
Epifix Product Overview. Available from: https://mimedx.com/epifix/.
About Grafix. Available from: http://www.osiris.com/grafix/healthcare-professionals/#about.
Mostow EN, Haraway GD, Dalsing M, Hodde JP, King D. Effectiveness of an extracellular matrix graft (OASIS Wound Matrix) in the treatment of chronic leg ulcers: a randomized clinical trial. J Vasc Surg. 2005;41(5):837–43.
Niezgoda JA, Van Gils CC, Frykberg RG, Hodde JP. Randomized clinical trial comparing OASIS Wound Matrix to Regranex Gel for diabetic ulcers. Adv Skin Wound Care. 2005;18(5 Pt 1):258–66.
Cazzell SM, Lange DL, Dickerson JE Jr, Slade HB. The management of diabetic foot ulcers with porcine small intestine submucosa tri-layer matrix: a randomized controlled trial. Adv Wound Care. 2015;4(12):711–8.
Schulz A, Depner C, Lefering R, Kricheldorff J, Kastner S, Fuchs PC, et al. A prospective clinical trial comparing Biobrane((R)) Dressilk((R)) and PolyMem((R)) dressings on partial-thickness skin graft donor sites. Burns. 2016;42(2):345–55.
Prasad JK, Feller I, Thomson PD. A prospective controlled trial of Biobrane versus scarlet red on skin graft donor areas. J Burn Care Rehabil. 1987;8(5):384–6.
Feldman DL, Rogers A, Karpinski RH. A prospective trial comparing Biobrane, Duoderm and xeroform for skin graft donor sites. Surg Gynecol Obstet. 1991;173(1):1–5.
Barret JP, Dziewulski P, Ramzy PI, Wolf SE, Desai MH, Herndon DN. Biobrane versus 1% silver sulfadiazine in second-degree pediatric burns. Plast Reconstr Surg. 2000;105(1):62–5.
Gerding RL, Emerman CL, Effron D, Lukens T, Imbembo AL, Fratianne RB. Outpatient management of partial-thickness burns: Biobrane versus 1% silver sulfadiazine. Ann Emerg Med. 1990;19(2):121–4.
Driver VR, Lavery LA, Reyzelman AM, Dutra TG, Dove CR, Kotsis SV, et al. A clinical trial of Integra Template for diabetic foot ulcer treatment. Wound Repair Regen. 2015;23(6):891–900.
Campitiello F, Mancone M, Della Corte A, Guerniero R, Canonico S. To evaluate the efficacy of an acellular Flowable matrix in comparison with a wet dressing for the treatment of patients with diabetic foot ulcers: a randomized clinical trial. Updat Surg. 2017;69(4):523–9.
Wainwright DJ. Use of an acellular allograft dermal matrix (AlloDerm) in the management of full-thickness burns. Burns. 1995;21(4):243–8.
Sinha UK, Shih C, Chang K, Rice DH. Use of AlloDerm for coverage of radial forearm free flap donor site. Laryngoscope. 2002;112(2):230–4.
Sinha UK, Chang KE, Shih CW. Reconstruction of pharyngeal defects using AlloDerm and sternocleidomastoid muscle flap. Laryngoscope. 2001;111(11 Pt 1):1910–6.
Kellner DS, Fracchia JA, Voigt E, Armenakas NA. Preliminary report on use of AlloDerm for closure of intraoral defects after buccal mucosal harvest. Urology. 2007;69(2):372–4.
Pushpoth S, Tambe K, Sandramouli S. The use of AlloDerm in the reconstruction of full-thickness eyelid defects. Orbit. 2008;27(5):337–40.
Deneve JL, Turaga KK, Marzban SS, Puleo CA, Sarnaik AA, Gonzalez RJ, et al. Single-institution outcome experience using AlloDerm(R) as temporary coverage or definitive reconstruction for cutaneous and soft tissue malignancy defects. Am Surg. 2013;79(5):476–82.
Park JY, Lee TG, Kim JY, Lee MC, Chung YK, Lee WJ. Acellular dermal matrix to treat full thickness skin defects: follow-up subjective and objective skin quality assessments. Arch Craniofac Surg. 2014;15(1):14–21.
Bolton WD, Ben-Or S, Hale AL, Stephenson JE. Reconstruction of a long-segment tracheal defect using an AlloDerm conduit. Innovations. 2017;12(2):137–9.
Romanelli M, Dini V, Bertone MS. Randomized comparison of OASIS wound matrix versus moist wound dressing in the treatment of difficult-to-heal wounds of mixed arterial/venous etiology. Adv Skin Wound Care. 2010;23(1):34–8.
Romanelli M, Dini V, Bertone M, Barbanera S, Brilli C. OASIS wound matrix versus Hyaloskin in the treatment of difficult-to-heal wounds of mixed arterial/venous aetiology. Int Wound J. 2007;4(1):3–7.
Lev-Tov H, Li CS, Dahle S, Isseroff RR. Cellular versus acellular matrix devices in treatment of diabetic foot ulcers: study protocol for a comparative efficacy randomized controlled trial. Trials. 2013;14:8.
Oasis Wound Types. Available from: https://www.oasiswoundmatrix.com/wound-type.
Lal S, Barrow RE, Wolf SE, Chinkes DL, Hart DW, Heggers JP, et al. Biobrane improves wound healing in burned children without increased risk of infection. Shock. 2000;14(3):314–8; discussion 8–9.
Cassidy C, St Peter SD, Lacey S, Beery M, Ward-Smith P, Sharp RJ, et al. Biobrane versus duoderm for the treatment of intermediate thickness burns in children: a prospective, randomized trial. Burns. 2005;31(7):890–3.
Wood F, Martin L, Lewis D, Rawlins J, McWilliams T, Burrows S, et al. A prospective randomised clinical pilot study to compare the effectiveness of Biobrane(R) synthetic wound dressing, with or without autologous cell suspension, to the local standard treatment regimen in paediatric scald injuries. Burns. 2012;38(6):830–9.
Oasis Application. Available from: https://www.oasiswoundmatrix.com/application.
Biobrane Application. Available from: https://www.woundsource.com/product/biobrane.
Heimbach DM, Warden GD, Luterman A, Jordan MH, Ozobia N, Ryan CM, et al. Multicenter postapproval clinical trial of Integra dermal regeneration template for burn treatment. J Burn Care Rehabil. 2003;24(1):42–8.
Jeschke MG, Rose C, Angele P, Fuchtmeier B, Nerlich MN, Bolder U. Development of new reconstructive techniques: use of Integra in combination with fibrin glue and negative-pressure therapy for reconstruction of acute and chronic wounds. Plast Reconstr Surg. 2004;113(2):525–30.
Branski LK, Herndon DN, Pereira C, Mlcak RP, Celis MM, Lee JO, et al. Longitudinal assessment of Integra in primary burn management: a randomized pediatric clinical trial. Crit Care Med. 2007;35(11):2615–23.
Campitiello F, Della Corte A, Guerniero R, Pellino G, Canonico S. Efficacy of a new Flowable wound matrix in tunneled and cavity ulcers: a preliminary report. Wounds. 2015;27(6):152–7.
Integra Label. Available from: https://www.integralife.com/file/general/1459196235.pdf.
AlloDerm label. Available from: https://allergan-web-cdn-prod.azureedge.net/actavis/actavis/media/allergan-pdf-documents/labeling/alloderm/adm_ifu_121p0541f_t3.pdf.
Sclafani AP, Romo T 3rd, Jacono AA, McCormick S, Cocker R, Parker A. Evaluation of acellular dermal graft in sheet (AlloDerm) and injectable (micronized AlloDerm) forms for soft tissue augmentation. Clinical observations and histological analysis. Arch Facial Plast Surg. 2000;2(2):130–6.
Bochicchio GV, De Castro GP, Bochicchio KM, Weeks J, Rodriguez E, Scalea TM. Comparison study of acellular dermal matrices in complicated hernia surgery. J Am Coll Surg. 2013;217(4):606–13.
Cazzell S, Vayser D, Pham H, Walters J, Reyzelman A, Samsell B, et al. A randomized clinical trial of a human acellular dermal matrix demonstrated superior healing rates for chronic diabetic foot ulcers over conventional care and an active acellular dermal matrix comparator. Wound Repair Regen. 2017;25(3):483–97.
Hinchcliff KM, Orbay H, Busse BK, Charvet H, Kaur M, Sahar DE. Comparison of two cadaveric acellular dermal matrices for immediate breast reconstruction: a prospective randomized trial. J Plast Reconstr Aesthet Surg. 2017;70(5):568–76.
Banta MN, Eaglstein WH, Kirsner RS. Healing of refractory sinus tracts by dermal matrix injection with Cymetra. Dermatol Surg. 2003;29(8):863–6.
Dorweiler B, Trinh TT, Dunschede F, Vahl CF, Debus ES, Storck M, et al. The marine Omega3 wound matrix for treatment of complicated wounds: a multicenter experience report. Gefasschirurgie. 2018;23(Suppl 2):46–55.
Gravante G, Sorge R, Merone A, Tamisani AM, Di Lonardo A, Scalise A, et al. Hyalomatrix PA in burn care practice: results from a national retrospective survey, 2005 to 2006. Ann Plast Surg. 2010;64(1):69–79.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Cahn, B., Lev-Tov, H. (2020). Cellular- and Acellular-Based Therapies: Skin Substitutes and Matrices. In: Alavi, A., Maibach, H. (eds) Local Wound Care for Dermatologists. Updates in Clinical Dermatology. Springer, Cham. https://doi.org/10.1007/978-3-030-28872-3_15
Download citation
DOI: https://doi.org/10.1007/978-3-030-28872-3_15
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-28871-6
Online ISBN: 978-3-030-28872-3
eBook Packages: MedicineMedicine (R0)